Cholinergic Receptor, Nicotinic, beta 2 (Neuronal) (CHRNB2) Peptide
-
- Target See all CHRNB2 products
- CHRNB2 (Cholinergic Receptor, Nicotinic, beta 2 (Neuronal) (CHRNB2))
- Peptide Type
- Synthetic
- Origin
- Mammalian
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Western Blotting (WB), Immunohistochemistry (IHC)
- Sequence
- CKIEVKHFPF DQQNCTMKFR SWTYDRTEID LVLKSEVASL DDFTPSGEWD
- Characteristics
-
A synthetic peptide for use as a blocking control in assays to test for specificity of CHRNB2 antibody,
Alternative Names: CHRNB2 control peptide, CHRNB2 antibody Blocking Peptide, Anti-CHRNB2 Blocking Peptide, Cholinergic Receptor Nicotinic Beta 2 Blocking Peptide, EFNL3 Blocking Peptide
-
-
- Application Notes
- Optimal conditions should be determined by the investigator
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
- Buffer
- PBS
- Handling Advice
- Avoid repeated freeze/thaw cycles.
- Storage
- -20 °C
- Storage Comment
- Store at -20 °C long term.
-
- Target
- CHRNB2 (Cholinergic Receptor, Nicotinic, beta 2 (Neuronal) (CHRNB2))
- Background
- Mutations in nAChRs are found in a rare form of nocturnal frontal lobe epilepsy. Previously, some nAChR mutations have been described that are associated with additional neurological features such as psychiatric disorders or cognitive defects. A new CHRNB2 mutation located in transmembrane region 3 (M3), outside the known ADNFLE mutation cluster. The CHRNB2 mutation I312M, which occurred de novo in twins, markedly increases the receptor's sensitivity to acetylcholine. Phenotypically, the mutation is associated not only with typical ADNFLE, but also with distinct deficits in memory. The cognitive problems are most obvious in tasks requiring the organization and storage of verbal information.
- Molecular Weight
- 57 kDa
-